BioScrip (BIOS) Set to Announce Earnings on Tuesday

Share on StockTwits

BioScrip (NASDAQ:BIOS) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 6th. Analysts expect BioScrip to post earnings of ($0.07) per share for the quarter. BioScrip has set its FY18 guidance at ($0.40-0.34) EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). The firm had revenue of $175.79 million during the quarter, compared to analyst estimates of $169.00 million. On average, analysts expect BioScrip to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of BIOS stock traded up $0.06 on Tuesday, reaching $2.72. 82,117 shares of the company’s stock traded hands, compared to its average volume of 356,977. BioScrip has a 12-month low of $1.80 and a 12-month high of $3.26. The company has a market capitalization of $337.40 million, a price-to-earnings ratio of -6.17 and a beta of 0.07.

A number of brokerages have recently weighed in on BIOS. Zacks Investment Research upgraded BioScrip from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Wednesday, July 11th. BidaskClub upgraded BioScrip from a “buy” rating to a “strong-buy” rating in a report on Friday, September 21st. Finally, Barrington Research reiterated a “buy” rating and set a $4.00 price target on shares of BioScrip in a report on Friday, October 5th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $3.56.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

See Also: Why investors pay attention to retained earnings

Earnings History for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with's FREE daily email newsletter.

Leave a Reply